NANOBIOTIX ANNOUNCES FINAL DATA FROM PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) WITH IMMUNE CHECKPOINT INHIBITORS AS A 2L+ THERAPY IN ANTI-PD-1-RESISTANT PRIMARY CUTANEOUS MELANOMA

Reuters · 2d ago

Please log in to view news